NA
AXSM icon

NewEdge Advisors’s Axsome Therapeutics AXSM Stock Holding History

NewEdge Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+1,133
New +$246K ﹤0.01% 2553
2026
Q1 		– Sell
-50
Closed -$9.13K – 4150
2025
Q4 		$9.13K Buy
+50
New +$6.98K ﹤0.01% 3496
2023
Q1 		– Sell
-100
Closed -$7.71K – 3470
2022
Q4 		$7.71K Buy
+100
New +$5.98K ﹤0.01% 2451

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NewEdge Advisors's AXSM Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,133 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #2553 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in AXSM as recently as Q4 2025.

NewEdge Advisors first reported a position in AXSM in Q4 2022 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • NewEdge Advisors held 1,133 shares of Axsome Therapeutics worth $277K as of Q2 2026.
  • Axsome Therapeutics was a new NewEdge Advisors position in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2553 holding.
  • NewEdge Advisors first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.